By now, you have probably heard of GLP-1 agonists, like the popular semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). With the epidemic of overweight and obesity in our country, I cannot ignore the compelling data on GLP-1 agonists and weight loss. That being said, I have one concern that stands out when considering this class of medication - read my blog to learn more.

Insulin resistance means that the cells in the body have become less responsive to insulin, which leads to elevated insulin and blood sugar levels. This leads to more belly fat, hunger/cravings, and fatigue - and if left unchecked, can lead to type 2 diabetes, cardiovascular disease, and even many cancers. That’s why it’s critical to take insulin resistance seriously.